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Abstract: 
Neutral amino acid transporters of the SLC6 family are expressed at the apical membrane of kidney 
and/or small intestine, where they (re-)absorb amino acids into the body.  
In this review we present the results concerning the dependence of their apical expression with their 
association to partner proteins. We will in particular focus on the situation of B0AT1 and B0AT3, that 
associate with members of the renin-angiotensin system (RAS), namely Tmem27 and angiotensin-
converting enzyme 2 (ACE2), in a tissue specific manner. 
The role of this association in relation to the formation of a functional unit related to Na+ or amino 
acid transport will be assessed. We will conclude with some remarks concerning the relevance of this 
association to Hartnup disorder, where some mutations have been shown to differentially interact 
with the partner proteins. 
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Abbreviations: 
RAS : renin angiotensin system 
SLC : solute carrier 
HAT: heterodimeric amino acid transporters 
SGLT1 : sodium dependant glucose transporter 1 
MeAIB : methylaminoisobutyrate 
Ang : Angiotensin 
AT1R : Angiotensin II type 1 receptor 
AT2R : Angiotensin II type 2 receptor 
ACE : Angiotensin Converting Enzyme 
MasR : G protein-coupled receptor encoded by the mas protoncogene 
 
3 
The description of amino acid transport has greatly evolved in the last 50 years, from the original 
transport systems description to the molecular identification of the transporters. Transport systems 
were classified according to the physico-chemical properties, stereospecificity, size and charge of the 
amino acids transported, as well as the ion or pH dependency and/or inhibition by (synthetic) amino 
acids. 
Identification of the molecular correspondents of these systems in the early 90s was a great advance 
and allowed the development of the necessary tools to characterize the variability and the 
subcellular localization of these transporters. 
A new development in the characterization of amino acid transporters has appeared through the 
increasing evidence of their association with partner proteins. It is reasonable to assume that the 
partner proteins are selected in an evolutionary coherent process in order to impact on transporter 
function and form a functional unit. 
The following review will focus on SLC6 amino acid transporters, some of which have been shown to 
associate with partner proteins. The situation of these transporters is particularly interesting, as the 
partner proteins are tissue-specific and may thereby be linked to the etiology of Hartnup disorder. It 
is also interesting to note that these partner proteins were originally described because of their role 
in the renin angiotensin system (RAS) that is mainly known to regulate blood pressure and Na+ 
reabsorption. 
 
Amino Acid Transporters of the SLC6 Family 
The solute carrier family 6 (SLC6), is also called Sodium- and chloride-dependent neurotransmitter 
transporter family. It is formed by 21 members of about 600 amino acids and 12 transmembrane 
domains1, grouped by homology and divided in four branches (GABA, monoamine, amino acid I and 
amino acid II transporter branch) (Figure 1). The solutes transported by the members of this family 
range from neurotransmitters to osmolytes and amino acids. In contrast to channels, the 
transporters of the SLC6 family are never fully open, actively transport the substrates against a 
concentration gradient at a speed that is about 10’000 times slower than channels.  
Most of the neurotransmitter transporters are expressed in the central and peripheral nervous 
system in the presynaptic membrane of neurons and can be the target of pharmacological 
manipulation. They are characterized by the rapid regulation of their insertion in the membrane and 
their high affinity transport (micromolar range). The osmolytes betaine and taurine are also 
transported by members of the Slc6 family and have important osmoregulation functions on kidneys 
and brain. We will focus our attention on the amino acid transporters of the SLC6 family. For the 
purpose of this paper, the amino acid transporters were grouped by the physico-chemical properties 
of their substrates in neutral, neutral and cationic and imino transporters. The amino acid 
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transporter members of the SLC6 family are mainly expressed in the central nervous system and 
epithelial cells. With the exception of B0AT1 (Slc6a19), they are high affinity transporters with sodium 
dependence (symporters) with the number of Na+ varying from 1 to 3,2,3 whereas chloride 
dependence is variable. The majority of the transporters localize to the plasma membrane with the 
exception of NTT4 (Slc6a17), which was characterized as a vesicular transporter (Table 1). 
 
Neutral amino acids 
B0AT1 (Slc6a19) 
B0AT1 (Slc6a19) is the major neutral amino acid transporter in epithelial cells of kidney and small 
intestine. The sodium dependent transport of a broad range of neutral amino acids was functionally 
described as system B0 much earlier than the identification of the transporter.4, 5  The transporter 
was molecularly identified and characterized as a sodium and broad range neutral amino acids co-
transporter with low affinity (millimolar range).6-8 B0AT1 is only chloride sensitive but not dependent 
and does not transport biogenic amines or osmolytes.6, 7 B0AT1 mRNA is highly expressed in kidney 
proximal tubule and small intestine where the protein localizes to the brush border membrane of 
small intestine enterocytes and the early portion of the proximal kidney tubules (S1).9, 10 The 
transporter interaction with accessory proteins and its role in Hartnup disorder will be discussed in 
later sections.11-13 A knock-out mouse model of B0AT1 has recently been described and these mice 
were shown to display decreased intestinal and renal neutral amino acid transport, the latter leading 
to neutral aminoaciduria similar to Hartnup subjects (discussed later on this review). Lower body 
weights and weight loss of mice under low (6%) and high (40%) protein diets and a blunted insulin 
response was observed.14 
 
B0AT2/NTT7-3 (Slc6a15) 
B0AT2 has 35-40% identity to the epithelial transporter B0AT1 (Slc6a19). Even though it was 
molecularly identified before B0AT1, its function remained unknown for many years. It has a 
particular substrate specificity for branched chain amino acids like L-isoleucine, L-valine, L-leucine, L-
methionine, small amino acids like L-alanine and the imino acid L-proline, characteristics reminiscent 
of the IMINO system. The co-transport of amino acids with high affinity is sodium dependent and 
chloride sensitive. It was shown to be expressed in the brain (cortex, cerebellum and brain stem), 
kidneys, lungs, and testis.15, 16 The function of this transporter is not completely understood. In the 
central nervous system, B0AT2 is expressed mainly in the neurons, whereas kidney localization of the 
transporter was not solved. The knock-out mice demonstrate lower L-leucine accumulation in 
synaptosomes with mild behavioral alterations and normal viability.17 
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B0AT3 (Slc6a18) 
B0AT3 shares 50% identity with B0AT1 in rodents and humans. The gene SLC6A18 is arranged in 
tandem with SLC6A19 (B0AT1) on chromosome 5p15 in human.10 It is highly expressed in the apical 
membrane of the proximal tubules in the kidney and displays an axial arrangement complementary 
to B0AT1 along the proximal tubule, being higher in the more distal segments (S2, S3). Functionally, 
B0AT3 was shown to transport a broad range of neutral amino acids as for B0AT1, but with high 
affinity (micromolar range) in a sodium and chloride dependent manner. As for B0AT1, B0AT3 
requires an accessory protein to be correctly expressed at the membrane.12, 18, 19 B0AT3 appears to be 
required for the reabsorption of tubular amino acids leftover by B0AT1 in the early proximal kidney 
tubule segments or amino acids that have leaked back through the paracellular pathway.20 In a 
knock-out mouse model of slc6a18, an abnormal excretion of several neutral amino acids was 
observed, especially glycine and L-glutamine. The mice otherwise develop normally and are viable 
but have been shown to develop high blood pressure under stress conditions.18, 21 In humans, the 
connection between single nucleotide polymorphism, high blood pressure or myocardial infarction 
has been examined and remained inconclusive.22, 23 
 
Glyt1 (Slc6a9) 
Glyt1 is expressed in brain, lung, kidney, small intestine, pancreas and liver.24, 25 In brain, it is 
expressed in glial processes close to inhibitory neurons which use glycine as a neurotransmitter. 
When over-expressed in polarized epithelial cells, the isoforms Glyt1a and Glyt1b localize to the 
apical and basolateral membranes, respectively. It induces a high affinity (micromolar range) sodium 
and chloride dependent uptake of glycine.26 Glyt1 knock-out mice suffer severe motosensory and 
respiratory deficits, and die shortly after birth.27 Nothing is described about the role of Glyt1 deletion 
on epithelial cells of the kidney or small intestine. 
 
Glyt2 (Slc6a5)  
Glyt2 is mainly expressed in brain, more precisely in axons and presynaptic terminals of inhibitory 
neurons that secrete glycine. When overexpressed in polarized epithelial cells it localizes to the 
apical membrane and like Glyt1, induces a high affinity (micromolar range) sodium and chloride 
dependent uptake of glycine.28 The ablation of slc6a5 gene in mice impairs high-affinity glycine 
uptake in brain areas with glycine-mediated transmission. The mice appeared to be normal at birth 
but die prematurely, displaying severe neuromotor alterations.29 
 
NTT4 (Slc6a17) 
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The so called neurotransmitter transporter-4 (NTT4), member 17 of the Slc6 family was also 
identified in the early 90’s, but remained an orphan transporter for many years.30 It has high identity 
(60%) with B0AT2 (Slc6a15), is sodium dependent but chloride independent as B0AT1 and 2 (Slc6a19 
and 15, respectively). It transports L-proline, and neutral amino acids (L-alanine, glycine and L-
leucine) like B0AT2 but with low affinity. It differs from the other members of the family by being a 
vesicular transporter rather than a plasma membrane transporter.31, 32 It is expressed in brain, more 
specifically in glutamatergic and gabaergic neurons.30 In the kidneys, it was shown to be highly 
expressed at the mRNA level in the medullary and cortical thick ascending limb and more distal 
nephron segments.33 The function of this transporter is still not clear and a knock-out mouse model is 
not available yet.  
 
Cationic and neutral amino acids 
ATB0,+ (Slc6a14) 
ATB0,+ is a sodium and chloride dependent high affinity transporter for almost all neutral and cationic 
amino acids. ATB0,+(slc6a14) shares moderate identity with B0AT1 (30% protein identity). The mRNA 
is highly expressed in brain, salivary and mammary glands, lungs and large intestine.34, 35 A knock-out 
mouse model is not available yet.  
 
Imino acids 
SIT1 (Slc6a20) 
SIT1 co-transports with high affinity (micromolar range) L-proline, methylaminoisobutyrate (MeAIB), 
methyl-proline, and hydroxyproline with sodium and chloride and escapes β-alanine inhibition. 
In mouse SIT1 is encoded by Slc6a20a (XT3s1) whereas the product of a second closely related gene 
Slc6a20b (XT3) does not lead to any uptake.36 There is however only one gene in human.  The mRNA 
is highly expressed in small intestine, kidney, lungs, spleen, thymus, testis, and brain. The protein 
localizes to the brush border membrane of the proximal tubules (S1=S2=S3) and enterocytes.10, 37 
SIT1, as B0AT1 and 3 (Slc6a19 and 18), may also functionally interact with accessory proteins. SIT1 
transporter represents the molecular component of the previously described IMINO system. Other 
transporters, using proton as driving force (PAT1 and PAT2 or Slc36a1 and 2, respectively), were also 
described to transport imino acids and additionally glycine and β-alanine in intestine and kidney.36-40 
There is no knock-out mouse model for SIT1 (slc6a20) yet.  
 
PROT (Slc6a7) 
PROT is a specific L-proline transporter expressed in brain, more specifically in glutamatergic 
neurons. It is a high affinity sodium and chloride dependent transporter.41  
7 
 
Partner Proteins 
Some carriers were shown to interact with other proteins for appropriate localization/expression 
and/or function. The interaction guarantees the insertion of the transporter in the membrane and 
may modulate the activity or the supply of substrate. The amino acid transporters accessory partner 
proteins have been shown to be implicated in a variety of cellular or physiological functions such as 
cell surface antigens (CD98), endoplasmic reticulum proteins (GTRAP3-18 or 41), other amino acid 
transporters (TAT1-4F2hcLAT2 or ASCT2-4F2hc-LAT1) and the renin angiotensin system (RAS). The 
mechanisms of interaction are variable and will be discussed in the following section.  
 
Heavy chains and the heterodimeric amino acid transporters (slc3 family) 
The interaction of amino acid transporters of the Slc7 family with type II glycoproteins of the Slc3 
family is necessary for a correct targeting of the transporter-complex to the plasma membrane. The 
so called heterodimeric amino acid transporters (HAT) family is formed by an amino acid transporter 
or light chain (Slc7 members) which interact with the surface antigen CD98/4F2hc or rBAT (related to 
b0,+ amino acid transporter). rBAT and 4F2hc are also called heavy chains, and are the only members 
of the solute carrier 3 family (Slc3a1 and 2, respectively). To this day, b0,+AT (Slc7a9) is the only 
member of the SLC7 family that was shown to interact with rBAT , while several transporters interact 
with 4F2hc (namely LAT1, LAT2, y+LAT1, y+LAT2, xCT, Asc-1 (Slc7a5, 8, 7, 6, 11 and 10, respectively)). 
rBAT and 4F2hc share 30% identity and target to different membrane compartments in polarized 
epithelial cells, rBAT being directed to the apical membrane and 4F2hc to the basolateral one.42 The 
interaction of 4F2hc or rBAT with the HAT transporters was shown to be made via a disulfide 
bridge.43  
When over-expressed together in cell line models, the heavy chain rBAT (Slc3a1) is mostly expressed 
as a complex with b0,+AT (Slc7a9). When expressed alone, rBAT remains endoglycosidase H sensitive, 
is disposed by the ER-mannosidase-dependent ERAD pathway and degraded.44 Recently, a trafficking 
signal on the transporter or light chain (Slc7a9) was suggested to define the fate of the complex. If 
the complex rBAT-b0,+  is formed, rBAT will be able to leave the ER, go through full glycosylation and 
rBAT-b0,+ will reach the membrane as an active complex. The deletion or mutation of the C-terminal 
signal of b0,+AT (Slc7a9) does not prevent complex formation, but leads to the formation of an 
inactive complex.45 Interestingly, mutations in the gene encoding the heavy chain or accessory 
protein rBAT (Slc3a1) as well as in its interacting light chain b0,+AT (Slc7a9) are associated with the 
autosomal disease cystinuria. Mutations on the gene encoding 4F2hc (Slc3a2), which associates with 
several members of the Slc7 family, are not connected to any physiological anomaly.46   
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Modulating interacting proteins (GTRAP3-18 or 41, negative modulators of Slc1 family members) 
Members of the glutamate and aspartate transporters from the solute carrier family 1 (Slc1) were 
shown to be modulated by the Glutamate TRansport Associated Protein for EAAT3 (Slc1a1) and 
EAAT4 (Slc1a6) (GTRAP3–18 or 41). GTRAPs are structurally homologous to the Ras superfamily in 
their secondary structure and molecular weight, but lack a GTP-binding consensus motif. GTRAP3-18 
is an integral endoplasmic reticulum (ER) membrane protein with four transmembrane domains and 
cytosolic N and C termini.47 GTRAP3–18 interacts with the carboxy-terminal end of the transporter 
and regulates the function of EAAT3/EAAC1 (Slc1a1) by delaying its exit from the ER.47 GTRAP3-18 is 
expressed in the same tissues EAAT3 is present in,48 and the interaction of EAAT3 in the ER with 
GTRAP3-18 oligomer protein may prevent the complex from exiting as cargo proteins to the Golgi.  
 
Functional interaction: TAT1 / LAT2-4F2 and ASCT2 / LAT1-4F2 
The functional interaction of antiporter transporters with other carriers has been shown to provide 
substrates to one of the carriers and to control cell volume and apoptosis. The interaction is only 
functional, no physical interaction was observed between the transporters involved. The first 
described interaction of this kind was among transporters expressed on the basolateral membrane of 
epithelial cells of the kidney proximal tubules involving an amino acid uniporter and an amino acid 
antiporter. The substrates transported from the cytoplasm to the extracellular compartment of the 
cells by the uniporter TAT1 (Slc16a10) can be used as substrate of the antiporter or obligatory 
exchanger LAT2-4F2hc (Slc7a8-Slc3a2) and possibly by y+LAT1-4F2hc (Slc7a7-Slc3a2).49 The uniporter 
has a very narrow specificity and low affinity, transporting only aromatic amino acids. The exchanger 
LAT2-4F2hc can import the effluxed aromatic amino acids outside of the cells in exchange for 
cytoplasmic neutral amino acids. The aromatic amino acid can again be recycled by the uniporter, 
triggering the efflux of neutral amino acids by the exchangers, favoring re-absorption. Whether this 
interaction triggers a cascade of events in the epithelial cells, which might control the transport by 
changing the expression of the transporter or its presence at the membrane has not been elucidated 
yet.    
The interaction between the symporter ASCT2 (Slc1a5) and the antiporters of the HAT family LAT1-
4F2hc (Slc7a5-Slc3a2), was shown to trigger an activation cascade upstream of the mTOR pathway 
that was independent of insulin.50 L-glutamine transported into cells by ASCT2 triggers the transport 
of essential amino acids by LAT1-4F2hc. The high intracellular concentration of L-glutamine and the 
later accumulation of essential amino acids into the cytoplasm activate rapamycin-sensitive mTOR 
complex 1 (mTORC1). This two steps amino acid exchange is necessary to activate the downstream 
cascade with phosphorylation and activation of the 70 kDa ribosomal protein S6 kinase (S6K), induce 
cell growth and inhibit autophagy. This work proposes a functional interaction between amino acid 
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transporters upstream of mTOR that is necessary to activate the pathway. In addition, these results 
suggest that the expression levels of the transporters may also be related to cell division, survival and 
recovering of the tissue when exposed to different diets or after injury.   
 
Solute transport and the renin angiotensin system 
Neutral amino acid transporters of the SLC6 family have recently been shown to rely on the 
expression of Tmem27 and the angiotensin-converting enzyme 2 (ACE2), two members of the RAS. 
The RAS is critical in the regulation of blood pressure homeostasis, electrolyte balance and 
extracellular volume. The main effector of the RAS is the key component angiotensin (Ang) II that 
mediates the majority of its cardiac and renal actions by binding Ang II type 1 receptor (AT1R).51, 52 
Responses include vascular smooth muscle contraction, enhanced myocardial contractility, 
aldosterone secretion, catecholamine release from medulla and sympathetic nerve endings, 
adrenergic stimulation, increased sympathetic nervous system activity, renal sodium reabsorption 
and thirst and salt appetite stimulation.53, 54 Ang II also binds to Ang II type 2 receptor (AT2R), 
inducing a counter regulatory vasodilation  through the stimulation of (NO)/cGMP, mediated by 
bradykinin release (aorta, heart, kidney), but also growth inhibition and apoptosis promotion.55 
In recent years, it has become clear that the RAS functions at two levels, the classical systemic RAS, 
as well as the local, tissue or intrinsic RAS. 
Systemic RAS leads to the generation of circulating Ang II through a series of cleaving events. The 
decapeptide precursor angiotensinogen (AGT) produced by the liver is first cleaved by the protease 
renin secreted by kidney juxtaglomerular cells in response to low effective circulating volume to the 
octapeptide Ang I. Ang I is then itself cleaved to Ang II by the dipeptidyl carboxypeptidase 
angiotensin converting enzyme (ACE) that is highly expressed on the surface of endothelial cells of 
the pulmonary circulation (Figure 2a). 
 
ACE2 (ACEH) 
The classical RAS view was complemented by the discovery of ACE2, an ACE homologue sharing 
41.8% sequence identity with its extracellular domain that was originally identified in a screen for 
metalloproteases as well as a human heart failure ventricle library (Figure 2b).56, 57 ACE2 was also 
found to play a role in the regulation of Ang II levels, although in contrast to ACE, the catalytic site of 
ACE2 only displays a single HEMGH zinc-binding catalytic domain. Another difference relies in the 
fact that ACE2 functions as a carboxypeptidase, which cleaves the terminal hydrophobic/basic amino 
acid following a L-proline (± 1-3 residues)58. 
ACE2 expression was measured in kidney, heart, testis, vascular smooth muscle cells, lung, liver, 
small intestine, placenta and brain, and localizes to the apical membrane in polarized cells.59 
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Expression at the membrane is down regulated after extracellular shedding by the ADAMs family of 
zinc metalloproteinases,60 and by binding of the SARS coronavirus.61, 62 
The crucial role of ACE2 in the RAS relies on its ability to cleave Ang I and Ang II to Ang (1-9) and Ang 
(1-7), respectively (Figure 2a).56, 57 The difference in protease target recognition is essential for the 
opposing functions of ACE and ACE2. Indeed, cleavage of Ang II by ACE2 not only decreases its 
bioavailability but also leads to the formation of Ang (1-7), that can bind to the G protein-coupled 
receptor encoded by the mas proto-oncogene (MasR), opposing AT1R-mediated vasoconstriction and 
cellular proliferation.63, 64 
Furthermore, ACE2 is involved in cardiovascular and renal (patho)physiology, as well as in diabetes, 
acute lung disease and pregnancy.59  
 
Tmem27 (Collectrin) 
Tmem27 or Collectrin is a homologue of ACE2 that shares 47.8% identity with its non-catalytic 
extracellular, transmembrane and cytosolic domains.65 Tmem27 was originally described as 
dramatically up regulated in 5/6 nephrectomized mouse kidney (NX-17) in a screen to identify genes 
involved in glomerular hyperfiltration and hypertrophy.66 The tmem27 gene is located next to ace2 
on chromosome Xp22 and encodes a 222 amino acid protein with a signal peptide that represents a 
32 kDa membrane glycoprotein with a single transmembrane segment (Figure 2b).65 Tmem27 has 
been shown to be expressed in liver, lung, endocrine pancreas and kidney proximal tubule brush 
border membrane and collecting duct, hence the misleading name Collectrin.12, 13, 67, 68  
Given the lack of Tmem27 catalytic activity, it does not seem to play a role in the classical RAS 
although an implication in the development of salt sensitive hypertension has been suggested.69 
Tmem27 has been shown to bind proteins involved in intracellular and membrane protein trafficking 
and ciliary movement such as γ-actin-myosin II-A, snapin, SNAP-25, and polycystin-2-polaris 
complexes. This may constitute the link between Tmem27 and its implication in glucose-stimulated 
insulin exocytosis and and/or ß-cell mass in pancreas,68, 67 as well as renal collecting duct primary 
cilium formation and polycystic kidney disease.70  
As described more in detail in later paragraphs, Tmem27 has also been shown to be critical for the 
correct expression of amino acid transporters in kidney.12, 13  
 
Local RAS 
The notion of local, intrinsic or tissue RAS has emerged in recent years in complement to the general 
circulating RAS. Tissues exhibiting expression of some RAS components include the lung, pancreas, 
liver, intestine, heart, kidney, vasculature, carotid body and adipose tissue, as well as the nervous, 
reproductive and digestive systems.71, 72 Local RAS action has been shown to be implicated in a wide 
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variety of functions distinct from the circulating RAS such as cell growth, anti-proliferation and 
apoptosis, reactive oxygen species (ROS) generation, pro-inflammatory and pro-fibrogenic actions, 
hormonal secretion, and also nutrient transport.53, 73, 74 
 
Role of local ACE2 
The kidney is particular in the regulation of its local RAS, as it expresses all the RAS components from 
renin to the AT receptors. The regulation of local Ang II levels was not always clear as it is difficult to 
discriminate locally synthesized components from those provided by the circulation and because 
renal RAS is compartmentalized between tubular, interstitial and intracellular systems. 
Cleavage of Ang I to Ang II is mainly performed by ACE that, in kidney, mostly localizes to the brush 
border membrane of the proximal tubule in human, in contrast to rats that also display localization 
on vascular endothelial cells and the basolateral side.75 The resulting levels of Ang II are up to a 100 
times higher than in plasma, which argues in favor of a local RAS as these levels cannot be achieved 
by the systemic supply alone.76  
Physiological actions of Ang II occur in the proximal tubule and further along the nephron in the 
distal segments and the collecting duct.77 The Ang II locally produced favors Na+ retention through 
the modulation of renal hemodynamics (decreased renal blood flow and glomerular filtration rate, 
afferent and efferent arteriole constriction and enhanced tubuloglomerular feedback) and increased 
Na+ transport.  
The increase of Na+ re-absorption induced by Ang II in proximal and distal tubules is mediated by 
activation of AT1R.78 In the proximal tubules, Ang II favors the expression of the H+-ATPase 
expression, thereby increasing transcellular sodium reabsorption through the Na+/H+ exchanger.79-83  
As described previously, renal SLC6 members co-transport Na+ and thereby participate in Na+ re-
absorption. A possible hypothesis is that the interaction of these Na+ co-transporters with ACE2, the 
enzyme counter regulating Ang II amounts and effects, could be a fine tuning mechanism to control 
Na+ reabsorption. The functional link would explain the dependence of these amino acid transporters 
on elements of the RAS. Such a hypothesis has however not been tested until now, and this 
mechanistic link might have been lost through evolution by the shift of the partner protein from 
ACE2 to Tmem27 in the kidney.  
The role of local RAS in small intestine and the expression of RAS components in enterocytes have 
led to the investigation of its impact on nutrient absorption.84 Local intestinal RAS system has also 
been shown to regulate sodium dependent glucose transporter 1 (SGLT1, Slc5a1) expression in rat 
small intestine. There, SGLT1-mediated glucose transport in intestinal ring segments was decreased 
by exposure to Ang II through transporter down regulation, which was reversible by AT1R antagonist 
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treatment.84 Additionally, ACE2 gene expression in Caco2 cells was induced by high glucose 
treatment.85 
We could however demonstrate that the expression of ACE2 on the apical membrane of enterocytes 
as well as Tmem27 in kidney is necessary for the expression of amino acid transporters. Members of 
the Slc6 family transporters, more specifically the neutral amino acid transporters B0AT1 and 3 
(Slc6a19 and 18) and imino transporter SIT1 (Slc6a20) interact with Tmem27 and ACE2, but not with 
ACE. The interaction mechanism of the transporters with the accessory proteins is not completely 
elucidated, but has been speculated by several groups.  
 
Neutral amino acid transporters associate with Tmem27 and ACE2 
Tmem27 and ACE2 partner proteins 
B0AT1 and B0AT3 were first shown to rely on Tmem27 expression to be correctly expressed at the 
brush border membrane of renal proximal tubule cells. Indeed B0AT1 and B0AT3 were strongly down 
regulated in the kidneys of tmem27 knock-out mice which led to massive amounts of amino acids 
lost in the urine.12, 13 
Discovery of ACE2 as a second partner protein for B0AT1 arose when the transporter was observed to 
be normally localized at the membrane of small intestine enterocytes of tmem27 knockout mice, but 
absent from knock-out mice for its homologue ACE2.9, 11 
 
Partner in kidney 
Tmem27’s role as a partner protein of amino acid transporters was revealed by gene ablation. Two 
independent groups generated tmem27 (coll) knock-out mice and observed a strong generalized 
neutral aminoaciduria, but no glucosuria or phosphaturia. Kidney morphology of tmem27 knock-out 
mice was normal and the mice were fertile and viable.12, 13 Analysis of amino acid transporters 
expression in kidney showed normal RNA but abnormal protein expression in proximal tubules with 
reduced transport function. The membrane expression of the neutral amino acid transporters of the 
Slc6 family, B0AT1, B0AT3 (Slc6a19 and 18), the imino transporter SIT1 (Slc6a20) but also Slc1 L-
glutamate and L-aspartate transporter EAAT3 (Slc1a1) were abolished or strongly reduced. 12, 13   The 
accumulation of neutral amino acids was shown to be decreased in renal brush border membrane 
vesicles of tmem27 knock-out mice. To confirm the interaction, the function of the transporters was 
assayed in the Xenopus laevis heterologous expression system. The presence of Tmem27 increased 
transporter function and accelerated expression kinetics. Interestingly, the expression of human 
B0AT1 with human Tmem27 induced a stronger effect on B0AT1 function than the mouse Tmem27 
ortholog. Tmem27 orthologs share 84% identity and the dissimilar residues are distributed in all 
segments of the protein. The C-terminal domain of Tmem27 appear to be involved in the interaction 
13 
with B0AT1 according to our split ubiquitin experiments (unpublished data), but the role of this 
domain or of the specific residues were not studied yet.  
The association between Tmem27 and B0AT1 may occur through non-covalent interactions in 
contrast to Slc3 (4F2hc or rBAT) and Slc7 members. The proteins co-localize at the apical membrane 
and the surface expression of B0AT1 is increased by Tmem27 presence in vitro and in vivo. In vitro, 
the surface expression increase suggests a chaperone function, but the impact on the function was 
much sturdier than the effect seen on the surface expression of the protein. This would suggest that 
the association may also impact transporter function, possibly by increasing the cycling rate. 
 
Other members of the SLC6 family interacting with Tmem27 in kidney 
The function of other members of the Slc6 family was also modulated by Tmem27. B0AT3 (Slc6a18) 
and SIT1 (Slc6a20) membrane expression were decreased in the brush border of tmem27 knock-out 
mice. Accordingly, the neutral aminoaciduria observed in these mice is broader than that typically 
observed in humans with Hartnup disorder that display mutations in B0AT1, and also extends to L-
proline suggesting the additional implication of the IMINO system. The loss of neutral amino acids in 
the urine, is probably caused by the decrease of both B0AT3 and B0AT1 (Slc6a18 and 19), however L-
proline is poorly transported by B0AT1 and 3.7, 12, 18, 86 This suggests that L-proline loss in urine might 
be due to the decreased expression of SIT1 (Slc6a20). Exogenous expression of B0AT3 with Tmem27 
in Xenopus laevis oocytes generates divergent results. Our own experiments showed that the 
expression of B0AT3 with Tmem27 (mouse or human orthologs) did not result in a substantial 
increase of transport function or membrane expression.18 However, Vanslambrouck and colleagues 
showed a more than 10 fold increase in function with the co-expression of mouse B0AT3 and 
Tmem27.19 To characterize the transport in heterologous expression system we overexpressed the 
transporter with the other member of the RAS system, ACE2 (Figure 3).  With this approach, we 
could characterize the function of mouse B0AT3 that had remained an orphan transporter until then.   
The protein interaction mechanism is unknown. It is interesting that B0AT3 readily reaches the 
membrane when overexpressed alone. In the presence of ACE2, we observed a slight increase of 
protein expression at the membrane, but most importantly, the function was revealed. The protein 
migrates equally when expressed in Xenopus laevis alone or in the presence of ACE2 or Tmem27.  In 
the native tissue, the transporter most likely interacts with Tmem27.10 
The axial gradient of B0AT3 along the proximal tubule corresponds to that of ACE2, i.e. higher 
expression in the later segments (S3), while Tmem27 expression follows the opposite trend. 
Interestingly, the ablation of ace2 neither interferes with B0AT3 expression on the apical membrane 
of the proximal tubules nor with the function of the transporter.  
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B0AT3 knock-out mice present mild aminoaciduria characterized by high excretion of glycine, L-
glutamine, L-methionine, L-alanine, L-threonine, L-serine, branched chain and aromatic amino acid. 
The urinary analysis of the ace2 knock-out mice showed no aminoaciduria. Knowing that the ablation 
of tmem27 induces a massive neutral aminoaciduria and decreases B0AT3 expression, it seems that 
Tmem27 is the partner of B0AT3 in the kidney.  
   
Partner in small intestine 
The transporter B0AT1 (Slc6a19) is highly expressed not only in kidney, where it interacts with 
Tmem27, but also in small intestine where Tmem27 is absent. We hypothesized that the transporter 
interacts with another RAS member expressed in the small intestine, namely ACE2. Using the knock-
out mouse model and an overexpression system, we could demonstrate that ACE2 is indeed the 
partner of B0AT1 in small intestine. The two proteins co-localize at the apical membrane of 
enterocytes of wild type mice and humans, and ACE2 could be co-immunoprecipitated with B0AT1 
antibody from brush border membrane preparations. In ace2 knock-out mice, expression of B0AT1 is 
completely abolished in the brush border of small intestine, but normal in kidney. Additionally, Na+ 
dependent transport of neutral amino acids was decreased in ace2 knock-out mice small intestine. 
The interaction was confirmed by the overexpression model, where co-expression with ACE2 
increased transporter membrane expression and function. Mouse and human ACE2 orthologs 
induced similar increases of transporter function unlike Tmem27, where only the human ortholog 
induced an effect on human B0AT1.9, 11  
Another transporter apparently having two tissue specific accessory proteins is SIT1 (Slc6a20). In the 
ace2 knock-out mice we observed a decrease in sodium dependent, pH independent L-proline 
transport (unpublished results). 
The interaction mechanism of B0AT1 (Slc6a19) with ACE2 is also not known. Based on the analysis of 
several B0AT1 mutants, we postulate that the absence of ACE2 may cause a decrease of transporter 
insertion or stability at the membrane. 
The physiological importance of this interaction could be explained from the transporter point of 
view. The ACE2 carboxypeptidase activity would provide substrate for the transporter with which it is 
interacting.9 This theory would explain the symbiosis between B0AT1 and ACE2 in the small intestine, 
since the carboxy amino acids released by ACE2 cleavage are mostly neutral amino acids, but also 
cationic.87 A catalytic dead mutant of ACE2 however still had the same effect on B0AT1 function. The 
slc6a19 knock-out model (B0AT1) has normal expression of ACE2 and Tmem27 suggesting that 
transporter ablation has no impact on RAS system members.88 We can therefore not conclude if the 
interaction also has a positive effect for the enzyme. Evidence however suggests that this is not the 
case, as the enzyme reaches the membrane in organs where the amino acid transporter is not 
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expressed, suggesting the interaction is important for the transporter but not crucial for RAS 
members.   
 
B0AT1, Tmem27, ACE2 and Hartnup disorder 
The aminoaciduria observed in tmem27 knock-out mice was shown to be caused by the reduction of 
amino acid reabsorption, and resembles the one observed in Hartnup disorder. Namely, elevated 
urinary excretion of neutral amino acids, absence of glucosuria or phosphaturia, and normal plasma 
amino acids levels. Neutral aminoaciduria is a hallmark of Hartnup disorder, as it is observed in all 
patients and is the first diagnostic of the disorder. Under certain conditions, patients may also 
additionally develop symptoms resembling pellagra (including light-sensitive dermatitis), intermittent 
cerebellar ataxia and psychosis-like symptoms.89  
Hartnup disorder is caused by mutations in gene SLC6A19 (chromosomal locus 5p15.33) encoding the 
B0AT1 transporter. Even though B0AT1 is the major neutral amino acid transporter in kidney and 
small intestine, patients develop normally and may present symptoms, other than the aminoaciduria, 
only under stress conditions (infections, malnutrition, etc.). The aminoaciduria is attributed to the 
defective transporter in kidney, but the impact of the transport defect on intestinal absorption and 
its connection to pellagra or neurological manifestations is still unclear.   
The first mutation of the SLC6A19 gene (B0AT1) was identified in members of the British Hartnup 
family, in which the disorder was originally described.90 Twenty-one additional mutations were 
further described to cause the disease, including deletions, missense, nonsense and splice site 
mutations on the gene SLC6A19, as depicted in Figure 4.90-93 Most of the patients are compound 
heterozygous which could partially contribute to the variable symptoms observed in patients (Table 
2).  
Knowing that B0AT1 interacts with Tmem27 in kidney and ACE2 in small intestine, a natural question 
is the role of these accessory proteins on the phenotype of the disorder. Both the ace2 and the 
tmem27 genes are located on the X chromosome (Xp22). So far, no X-linked recessive Hartnup or 
other neutral aminoaciduria disorders have been described. This suggests that mutations on the 
accessory protein are not the cause of the disorder. 
On the other hand, the mutated transporter may interact differently with the accessory proteins, and 
show a tissue dependent role. The mutations causing Hartnup disorder are distributed all over the 
protein. Using the crystallized structure of the Slc6 bacterial homologue LeuTaq,
94 we modeled B0AT1 
and could identify the sites where the mutations are possibly localized (Figure 4). The domain 
responsible for the interaction with the accessory proteins is not yet known, but some important 
regions and residues, like sodium and substrate binding domain or domains which undergo 
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conformational changes during the transport cycle, were identified based on LeuTaq and previous 
cysteine scan studies.  
The expression of B0AT1 containing Hartnup causing mutations with Tmem27 or ACE2 showed 
different effects on function and membrane expression of the transporter (Table 3). From the 
mutated transporters analyzed, we could identify an intriguing class of mutants (D173N and P265L) 
which differentially interacted with the two tissue-specific accessory proteins such that their function 
is stimulated only by the intestine-specific associated protein ACE2. The D173N allele was identified 
in different unrelated Hartnup pedigrees and displays a high heterozygote frequency in healthy 
Caucasians (1:122 healthy individuals).95 The interaction with ACE2 might allow the “survival” of this 
frequent allele by increasing the amino acid absorption in the individuals bearing the mutation. 
Unfortunately, no data on the intestinal absorption of patient bearing the D173N mutation is 
available. Another complicating factor would be the heterozygosis of the patients. Until now, only 3 
D173N homozygote mutant individuals have been identified in American and Australian pedigrees.  
A second class of mutants corresponds to those which are not stimulated by either associated 
protein (R240Q and A69T). R240Q interacts with the accessory protein, but there is no increase of 
surface appearance upon co-expression with ACE2 or Tmem27 when compared to the transporter 
expressed alone. In the case of A69T, the surface expression is increased. The results suggest a 
different fate for these mutations. R240Q may impact on the interaction with accessory proteins, 
whereas A69T, which is localized in a domain that undergoes conformational changes during the 
transport, reaches the membrane as a complex but cannot work properly.9, 11, 96   
The majority of the mutations tested (R57C, L242P, E501K, G93R and P579L) are dead mutants. They 
do not reach the membrane or display any measurable function. Finally, some mutations have not 
been assayed for the interaction with the tissue accessory proteins yet.  
 
The phenotype of Hartnup patients has been shown to be very variable. One of the reasons for the 
variation observed can be the nutritional status and diet of the subjects and their environment. 
Another cause of variation may be the high frequency of compound heterozygous. Additionally, 
B0AT1 mutants can interact differentially with tissue specific accessory proteins, favoring the 
absorption of amino acids in the intestine and might also contribute significantly to the phenotypic 
heterogeneity among individuals with Hartnup disorder. 
 
Conclusion and Outlook 
The work on amino acid transporters of the SLC6 family and their tissue-specific partner proteins has 
provided critical information concerning the modulation of amino acid transporter function, and the 
possible physiological relevance of such an association in the context of Ang II sensitivity. With this 
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information, new questions waiting to be solved have emerged concerning the exact beginning and 
extent of this association, as well as the mechanism guiding the selection of the Tmem27 partner 
protein in kidney, rather than ACE2 that is also expressed in that organ. Additionally, questions 
related to the regulation of the expression and function of the transporters and their accessory 
proteins by diet, gender, hormones, age and diseases are crucial and are just starting to be 
investigated. These questions will allow us to understand the complex mechanism of amino acids 
homeostasis maintenance and its relevance for several processes in the body distinct from the basic 
energy supply and protein synthesis. After the transporter cloning era, we predict an exciting 
translational era to answer old physiological questions related to amino acids transport.  
18 
 
Legends: 
Figure 1: Phylogenetic tree of human and mouse Slc6 family. Protein sequences of the human and 
mouse Slc6 family members were aligned and a phylogenetic tree was constructed. The Phylogeny.fr 
platform was used to construct the tree.97, 98 The members are divided in GABA (white, continuous 
line): hGAT1/SLC6A1, P30531; hGAT2/SLC6A13, Q9NSD5; hGAT3/SLC6A11, P48066; hTAUT/SLC6A6, 
P31641; hCT1/SLC6A8, P48029; hBGT1/SLC6A12, P48065; SLC6A10 hypothetic protein, Q6ZUB2; 
mGAT1/slc1a1, P31648;mGAT2/slc6a13, P31649; mGAT3/slc6a11, P31650; mbetaine, GABA/slc6a12, 
Q8VCS9; mCT1/slc6a8, Q8VBW1; mTAUT/slc6a6, O35316. Monoamines (white, dashed line):   
hNET/SLC6A2, P23975; hDAT/SLC6A3, Q01959; hSERT/SLC6A4, P31645, mNET/slc6a2, O55192; 
mDAT/slc6a3, Q61327; m5HTT/slc6a4, Q60857. Amino acids I (gray, dashed line):  hGlyt2/SLC6A5, 
Q9Y345; hGyt1/SLC6A9, P48067; hPROT/SLC6A7, Q99884; hB0+/SLC6A14, Q9UN76; mGlyt2/slc6a5, 
B2RQX9; mGlyt1/slc6a9, P28571; mPROT/slc6a7, Q6PGE7; mB0+/slc6a14, Q9JMA9. Amino acids II 
(orphans, gray, continuous line): hB0AT2/SLC6A15, Q9H2J7; hNTT5/SLC6A16, Q9GZN6; 
hNTT4/SLC6A17, Q9H1V8; hB0AT3/SLC6A18, Q96N87; hB0AT1/SLC6A19, NP_001003841.1; 
hSIT1/SLC6A20a, Q9NP91; mB0AT2/sl6a15, Q8BG16; mslc6a16, XM_355900.5; mNTT4/slc6a17, 
Q8BJI1; mB0AT1/slc6a18, O88576; mB0AT1/slc6a19, Q9D687; mSIT1/slc6a20a, NP_035861.2; 
mXT3/slc6a20b, O88575. 
 
Figure 2: Renin angiotensin system and its members.  a) Schematic representation of the renin–
angiotensin (RAS) system. The main role of the system involves ACE and the production of the 
octapeptide Angiotensin II. ACE2 role was suggested to be involved in the counterbalance effect of 
Angiotensin II and ACE activity. b) ACE2 and Tmem27 share high identity in the C-terminal domain. 
ACE2 and Tmem27 share identity in the C-terminus (white, shaded), whereas ACE and ACE2 in the N-
terminal extracellular domain (grey, vertical lines). Somatic ACE (sACE), ACE2 and Tmem27/Collectrin 
are type I integral proteins with a signal peptide in the N-terminal, transmembrane, and short C-
terminal domains. ACE2 and ACE have 1 or 2 zinc-binding motif (HEMGH) (bm) in the extracellular 
domain. sACE is encoded by a gene located on human chromosome 17, while ACE2 and Tmem27 on 
the X chromosome. Testis ACE was omitted from the schematic representation. AT1R, Angiotensin 
type 1 receptor; AT2R, Angiotensin type 2 receptor; MasR, G protein coupled Mas proto-oncogene 
receptor.  
 
Figure 3: ACE2 and TMEM27, but not ACE, functionally interact with B0AT3 and B0AT1. Mouse 
B0AT3 and 1 (Slc6a18 and 19, respectively) were expressed in Xenopus laevis oocytes alone or in 
combination with mouse Tmem27, ACE2 or ACE. Transporter alone (empty bars), co-expression with: 
Tmem27 (gray bars), ACE2 (checkered bars), ACE (solid bars). 10 ng of each cRNA was injected, and 
the transport of L-isoleucine (100 µM for B0AT3 and 1 mM B0AT1 for 30 minutes) measured after 6 
days expression. The low effect of Tmem27 in mouse B0AT1 after long expression was previously 
observed.11 ACE expression in tmem27 and ace2 knockout is normal, supporting the hypothesis that 
ACE is not an accessory protein even though in oocytes injected with B0AT1 the transport was 
increased.   
 
Figure 4: Mutations in the SLC6A19 gene causing Hartnup disorder. The homology model of human 
B0AT1 transport was based on the crystal structure of LeuTAa (NP_214423) as a template using the I-
TASSER server. 94, 99 The pdb file was visualized using Pymol (DeLano Scientific LLC, Palo Alto, CA). The 
transporter is oriented with the top facing the lumen of the renal proximal tubule or small intestine 
and the bottom facing the intracellular compartment. The mutations are from refs. 11, 90-93, 100, 101  
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Table 1: SLC6 human family members*.  
 
Gene Protein name Key substrate Ion 
dependence 
Tissue distribution chromosome 
SLC6A1  GAT1  GABA  Na+, Cl- central and peripheral neurons (gabaergic nerons) 3p25-p24
SLC6A2  NET , NAT1, NET1  norepinephrine Na+, Cl- central and peripheral neurons, adrenal gland, placenta 16q12.2
SLC6A3  DAT1 , DAT dopamine  Na+, Cl-  brain  (dopaminergic neurons)                                                             5p15.3 
SLC6A4  SERT , 5-HTT serotonin  Na+, Cl-, K+  central and peripheral nervous system, epithelial cells, 
platelets  
17q11.1-q12 
SLC6A5  GlyT2  glycine  Na+, Cl- spinal cord, brain (axon and presynaptic terminal of glycinergic 
neurons)  
11p15.2-15.1
SLC6A6  TauT  taurine  Na+, Cl-  brain, retina, liver, kidney, heart, spleen, pancreas  3p25-p24 
SLC6A7  PROT  L-proline  Na+, Cl-  brain (glutamatergic neurons) 5q31-q32 
SLC6A8  CT1, CRTR  creatine Na+, Cl- ubiquitous Xq28
SLC6A9  GlyT1  glycine  Na+, Cl-  brain, pancreas, uterus, stomach, spleen, liver, lung 1p33 
SLC6A11  GAT3, GAT-B, GAT-4  GABA  Na+, Cl-  brain (gabaergic neurons, glia)  3p25.3 
SLC6A12  BGT1  betaine, GABA  Na+, Cl-  kidney, brain  12p13 
SLC6A13  GAT2, GAT3   GABA  Na+, Cl- brain (meninges, ependymal, choroid plexus), retina, liver, 
kidney  
12p13.3
SLC6A14  ATB0,+  neutral, cationic amino 
acids  
Na+, Cl-  lung, trachea, salivary gland, mammary gland, stomach, colon, 
pituitary gland  
Xq23-q24 
SLC6A15  B0AT2, v7-3, NTT7-3   L-isoleucine Na+ brain (amygdala, putamen, corpus callosum) 12q21.3
SLC6A16  NTT5  Orphan transport  testis, pancreas, prostate  19q13.1 -
q13.4 
SLC6A17  NTT4, XT1   neutral amino acids  Na+  synaptic vesicles  1p13.3 
SLC6A18  XT2, B0AT3  Glycine,   L-glutamine Na+, Cl- kidney (apical) 5p15.33
SLC6A19  B0AT1, XT2s1 neutral amino acids  Na+  intestine and renal proximal tubule (apical)  5p15.33 
SLC6A20 SIT1, XT3s1, Xtrp3 imino acids  Na+, Cl-  intestine, kidney proximal tubule, choroid plexus, microglia, 
meninges of the brain, ovary 
3p21.3 
2 
*This table is based on the references cited along the section describing the amino acid transporters. For the monoamine, GABA and osmolyte transporter 
based on the work of Chen, Reith and Quick.2 The hypothetical proteins encoded by the genes SLC6A10 and 21 were not included in this table. 
1 
Table 2: Hartnup causing mutations – Identified mutations in the SLC6A19 gene encoding B0AT1.   
 
Pedigree Family Mutation Zygosity Symptoms 
 
Hartnup 
family 
UK a 
IVS8+2T→G homozygous Aminoaciduria, mild cerebral 
ataxia, light sensitive skin rash 
(pellagra-like) 
 
Japan a 884-885del TG 
(V295fsX351) 
homozygous I) Mental retardation, gait 
disturbances, sunlight  skin rash 
II) Psychological symptoms, 
ataxia and diplopia. 
 
Japan a 169C→T 
(R57C) 
homozygous Aminoaciduria, low plasma 
amino acid levels, light sensitive 
rush (pellagra-like) 
 
Japan a 340delC 
(L114FSX114) 
682-683AC→ TA  
(T228X) 
Compound 
heterozygous 
Aminoaciduria, asymptomatic 
 
USA 
a 
517G→A (D173N) Homozygous   Aminoaciduria, asymptomatic 
 
Australia 
b 
IVS8+2G 
725T→C (L242P) 
Compound 
heterozygous 
Aminoaciduria, asymptomatic 
 
Australia 517G→A (D173N)
1501G→A (E501K) 
Compound 
heterozygous 
Aminoaciduria, asymptomatic
 
Australia 
b, f 
IVS11+1A
719G→A (R240Q) 
Compound 
heterozygous 
Aminoaciduria, asymptomatic
 
Australia 
b  
517G→A (D173N)
 
homozygous Aminoaciduria, asymptomatic
 
Australia 
b, f 
517G→A (D173N)
196G→A   (G66R) 
Compound 
heterozygous 
Aminoaciduria, asymptomatic
 
Australia 
b, f 
517G→A (D173N)
1550A→G  (D517G) 
Compound 
heterozygous 
Aminoaciduria, asymptomatic
 
Australia 
b 
517G→A (D173N)
718C→T (R240X) 
Compound 
heterozygous 
Aminoaciduria, asymptomatic
 
Denmark 
c 
725T→C (L242P) 
794C→T 
(P265L) 
Compound 
heterozygous 
Pellagra-like skin rash, atactic 
gait 
 
Denmark 
c 
IVS8+2T→G
205C→A (A69T) 
Compound 
heterozygous 
Aminoaciduria, asymptomatic
 
Denmark 
c 
IVS8+2T→G 
1735C→G (P579L) 
Compound 
heterozygous 
Aminoaciduria, asymptomatic 
 
Germany 
c 
277G→A (G93R) homozygous Aminoaciduria, asymptomatic 
 
China 
d 
850G→A (G284R) homozygous Edema, involuntary movements 
of head and bilateral upper 
extremities history of dermatitis 
caused by photosensitivity. 
2 
 Korea 
e 
c.908C>T (S303L) 
c.1787_1788insG 
(T596fsX73) 
Compound 
heterozygous 
seizures, attention-deficit 
hyperactivity disorder, 
and mental retardation without 
pellagra or ataxia, 
aminoaciduria 
 Australia 
f 
196G→A   
(G66R)/277G→A 
(G93R) 
277G→A 
(G93R)/517G→A 
(D173N) 
517G→A 
(D173N)/850G→A  
(G284R) 
517G→A 
(D173N)/1550A→G  
(D517G) 
Compound 
heterozygous 
 
Compound 
heterozygous 
 
Compound 
heterozygous 
 
Compound 
heterozygous 
Aminoaciduria, asymptomatic 
 Canada 
f 
532C→T  
(R178X)/1213G→A  
(E405K) 
 517G→A 
(D173N)/982C→T 
(R328C) 
Compound 
heterozygous 
 
Compound 
heterozygous 
Aminoaciduria, asymptomatic 
Newborn screening 
 
a, 90, 100; b, 93, 101; c, 11, d, 92; e, 91; f, 102. 
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Table 3: SLC6A19 missense mutations shown to interact with Tmem27 
and/or ACE2. From the mutations co-expressed with the two accessory 
proteins, the majority caused a loss of surface expression (R57C, G93R, L242P, 
E501K, P579L) and the transporters were not functional alone or in co-
expression. Two mutations had low function as shown for the wild type 
expressed alone, but prevented both accessory proteins of stimulating the 
transport function (A69T and R240Q). Two mutations led to a differential 
interaction with the accessory proteins (D173N and P265L), only the intestinal 
accessory protein triggers an increase in cell surface expression and function.9, 
11 Several mutations were not yet assayed with the accessory proteins.  
 
Protein Position in the 
protein 
Co-expression with  Membrane 
expression 
Function 
R57C 1st TMS ACE2 and Tmem27 - - 
A69T 2nd TMS ACE2 and Tmem27 ↑ = 
G93R 2nd TMS ACE2 and Tmem27 - -
D173N 2nd EL ACE2  ↑ ↑ 
R240Q 3th EL ACE2 and Tmem27 = = 
L242P 3th EL ACE2 and Tmem27 - - 
P265L 6th TMS ACE2 ↑ ↑ 
E501K 10th TMS ACE2 and Tmem27 - - 
P579L 6th TMS ACE2 and Tmem27 - - 
G66R 2nd TMS nd   
G284R 6th TMS nd   
S303L 7th TMS nd   
R328C 7th TMS nd   
E405K 4th EL nd   
D517G 5th IL nd
nd, the function or membrane expression of these missense mutant were not 
yet determined in the presence of ACE2 or Tmem27 
 
 
 
 
 
 
 
 
 
  
